8-乙氧基-9-乙基-9H-嘌呤-6-胺 | 634924-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 8-乙氧基-9-乙基-9H-嘌呤-6-胺
• 英文名称: ANR 94
• 英文别名: 8-Ethoxy-9-ethyl-9H-purin-6-amine；8-ethoxy-9-ethylpurin-6-amine
• CAS: 634924-89-3
• 化学式: C₉H₁₃N₅O
• 分子量: 207.235
• InChiKey: QUGDTMONBLMLLD-UHFFFAOYSA-N

物化性质

• 沸点：
  394.4±45.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶1mg/mL，澄清（加热）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  8-bromo-9-ethyladenine 、 乙醇 在 sodium hydroxide 作用下， 生成 8-乙氧基-9-乙基-9H-嘌呤-6-胺
  参考文献：
  名称：

  New adenosine A2A receptor antagonists: Actions on Parkinson's disease models

  摘要：

  The 8-substituted 9-ethyladenine derivatives: 8-bromo-9-ethyladenine (ANR 82), 8-ethoxy-9-ethyladenine (ANR 94), and 8-furyl-9-ethyladenine (ANR 152) have been characterized in vitro as adenosine receptor antagonists. Adenosine is deeply involved in the control of motor behaviour and substantial evidences indicate that adenosine A(2A) receptor antagonists improve motor deficits in animal models of Parkinson's disease. On this basis, the efficacy of ANR 82, ANR 94, and ANR 152 in rat models of Parkinson's disease was evaluated. All compounds tested reversed the catalepsy induced by haloperidol. However, in unilaterally 6-hydroxydopamine-lesioned rats, only ANR 94 and ANR 152 potentiated L-dihydroxy-phenylalanine (L-DOPA) effect on turning behaviour and induced contralateral turning behaviour in rats sensitised to L-DOPA. Taken together the results of this study indicate that some 8-substituted 9-ethyladenine derivatives ameliorate motor deficits in rat models of Parkinson's disease, suggesting a potential therapeutic role of these compounds. (c) 2005 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejphar.2005.01.057

文献信息

• SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
  申请人：Jiang, Jean, X.

  公开号：EP3245204A1

  公开（公告）日：2017-11-22
• METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20150297623A1

  公开（公告）日：2015-10-22

  Embodiments of the invention are directed to administering a therapeutically effective amount of a purinergic P2 receptor agonist alone or in combination with adenosine receptor antagonist and/or other anti-cancer therapies for the treatment of cancer. Agonist for the P2 receptors include non-hydrolysable ATP analogs. In particular aspects the cancer is a metastatic cancer, such as a bone metastasis.
• Small Molecules for the Treatment of Primary Cancer and Cancer Metastasis
  申请人：Board of Regents, the University of Texas System

  公开号：US20210206769A1

  公开（公告）日：2021-07-08

  Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.
• SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
  申请人：JIANG Jean X.

  公开号：US20210361660A1

  公开（公告）日：2021-11-25

  Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purinergic receptor antagonist and/or adenosine receptor antagonists.
• [EN] METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS<br/>[FR] MÉTHODES DE TRAITEMENT D'UN CANCER PRIMAIRE ET DE LA MÉTASTASE CANCÉREUSE
  申请人：UNIV TEXAS

  公开号：WO2014074529A1

  公开（公告）日：2014-05-15

  Embodiments of the invention are directed to administering a therapeutically effective amount of a purinergic P2 receptor agonist alone or in combination with adenosine receptor antagonist and/or other anti-cancer therapies for the treatment of cancer. Agonist for the P2 receptors include non-hydrolysable ATP analogs. In particular aspects the cancer is a metastatic cancer, such as a bone metastasis.